Subject Index 767OMDM-2 200
opioid 575, 577, 578, 582, 584, 585,
590
opioid systems 706
morphine 706
opioids 129
oral fluid 679
p42/44 MAP kinase 610
pain, 26–28, 118, 124, 125, 127, 159,
167, 169, 171, 221, 317, 318,
379, 498, 520, 574, 720, 723,
724, 726, 727, 729, 730, 731,
732, 734, 735, 745, 746, 748
palmitoylethanolamide (PEA)
6, 22, 27, 28, 35, 190, 582
palmitylsulfonyl fluoride (AM374)
191
Paracentrotus lividus 287
parallel fibers 355
paralytic ileus 574, 588
parasympathetic nervous system
345
Parkinson’s disease 483, 491, 495,
496, 728
PEA seepalmitoylethanolamide
pelvic neurons 319
perception 447
periaqueductal gray/grey 315, 337,
339, 528
perinatal exposure to cannabinoids
643–645, 648–652
and gene expression 648, 649,
651, 652
effects on maturation of neuro-
transmitter systems 643,
644, 648–652
sexual dimorphism 643, 649–
652
peripheralnervoussystem 345,346
peripheral vascular resistance 604,
610, 615, 616
peristalsis 577, 578, 580
peroxynitrite 64
pertussis toxin (PTX) 609, 611, 612
PET 426, 439, 449
pharmacokinetics 657
pharmacophore(s) 270
aminoalkylindole 265
classical CB side chain 256
classical/non-classicalCB 254
endogenous CB 259
pharmacophore development
ligand–ligand 252
ligand–receptor 252
phenolic hydroxyl 257
phenylmethylsulfonyl fluoride 191
phospholipase A 58
phospholipase C (PLC) 58, 288
phosphorylation 68
phylogenetic 284
phytocannabinoid(s) 2, 13, 17
pithed rabbits 346
pithed rats 346
PKA 56, 432
plant(s) 286, 287, 293, 294
plasma 672
platelets 616
PMSF 192, 197
polymorphism 99
positronemissiontomography(PET)
426, 439, 449
potassium channels 3, 22, 34, 36,
37, 329, 349, 356
prefrontal cortex 313
pregnancy 563, 566
pressure-volumeconductancesystem
604, 613
presynaptic inhibition
vesicle release machinery 350
presynaptic axon terminal 356
presynapticinhibition 333,338,349
calcium channels 349
mechanism 349
potassium channels 349
primaryamoebicmeningoencephali-
tis 399
primary humoral immune response
390
primary sensory fibres 337
progesterone 566
prokaryotic 284